Bayer Decision to Advance IONIS-FXI-LRx Following Positive Results. See Also: Why Hepion Pharmaceuticals Stock Almost Doubled Today

Bayer Decision to Advance IONIS-FXI-LRx for Clotting Disorders
On October 9, 2019 Ionis Pharmaceuticals (IONS) announced it had been notified by its partner Bayer (This content is for paid subscribers.

Please click here to subscribe or here to log in.